These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15078136)

  • 41. Regulators of apoptosis: suitable targets for immune therapy of cancer.
    Andersen MH; Becker JC; Straten Pt
    Nat Rev Drug Discov; 2005 May; 4(5):399-409. PubMed ID: 15864269
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune Cells.
    Vahedi F; Nham T; Poznanski SM; Chew MV; Shenouda MM; Lee D; Ashkar AA
    Sci Rep; 2017 Sep; 7(1):12083. PubMed ID: 28935883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
    Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
    Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cellular immunotherapy of cancer.
    Yang JC
    Curr Opin Gen Surg; 1994; ():238-44. PubMed ID: 7583979
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adoptive T-cell therapy of cancer.
    Erbayraktar Z
    J BUON; 2009 Sep; 14 Suppl 1():S193-201. PubMed ID: 19785066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Benefits of a continuous therapy for cancer patients with a novel adoptive cell therapy by cascade priming (CAPRI).
    Wank R; Song X; Gu S; Laumbacher B
    Immunotherapy; 2014; 6(3):269-82. PubMed ID: 24762072
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Artificial antigen-presenting cells for use in adoptive immunotherapy.
    Turtle CJ; Riddell SR
    Cancer J; 2010; 16(4):374-81. PubMed ID: 20693850
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.
    Toes RE; Offringa R; Feltkamp MC; Visseren MJ; Schoenberger SP; Melief CJ; Kast WM
    Behring Inst Mitt; 1994 Jul; (94):72-86. PubMed ID: 7998917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decreased tumor surveillance after adoptive T-cell therapy.
    Matter M; Pavelic V; Pinschewer DD; Mumprecht S; Eschli B; Giroglou T; von Laer D; Ochsenbein AF
    Cancer Res; 2007 Aug; 67(15):7467-76. PubMed ID: 17671217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cell-Based Immunotherapy of Gliomas.
    Everson RG; Antonios JP; Liau LM
    Prog Neurol Surg; 2018; 32():90-100. PubMed ID: 29990977
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunotherapy with interferon-α-induced dendritic cells for chronic HCV infection (the results of pilot clinical trial).
    Chernykh E; Leplina O; Oleynik E; Tikhonova M; Tyrinova T; Starostina N; Ostanin A
    Immunol Res; 2018 Feb; 66(1):31-43. PubMed ID: 29164490
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells.
    Kleihauer A; Grigoleit U; Hebart H; Moris A; Brossart P; Muhm A; Stevanovic S; Rammensee HG; Sinzger C; Riegler S; Jahn G; Kanz L; Einsele H
    Br J Haematol; 2001 Apr; 113(1):231-9. PubMed ID: 11328306
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulation of antitumor immune responses by hematopoietic cytokines.
    Waller EK; Ernstoff MS
    Cancer; 2003 Apr; 97(7):1797-809. PubMed ID: 12655538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. gammadelta T cells in cancer immunotherapy: current status and future prospects.
    Chiplunkar S; Dhar S; Wesch D; Kabelitz D
    Immunotherapy; 2009 Jul; 1(4):663-78. PubMed ID: 20635991
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adoptive Cellular Therapy (ACT) for Cancer Treatment.
    Yang F; Jin H; Wang J; Sun Q; Yan C; Wei F; Ren X
    Adv Exp Med Biol; 2016; 909():169-239. PubMed ID: 27240459
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
    Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
    J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
    Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
    Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles.
    Rosalia RA; Silva AL; Camps M; Allam A; Jiskoot W; van der Burg SH; Ossendorp F; Oostendorp J
    Cancer Immunol Immunother; 2013 Jul; 62(7):1161-73. PubMed ID: 23613147
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression.
    Fong CL; Mok CL; Hui KM
    Gene Ther; 2006 Feb; 13(3):245-56. PubMed ID: 16163376
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An autologous dendritic cell vaccine polarizes a Th-1 response which is tumoricidal to patient-derived breast cancer cells.
    Tomasicchio M; Semple L; Esmail A; Meldau R; Randall P; Pooran A; Davids M; Cairncross L; Anderson D; Downs J; Malherbe F; Novitzky N; Panieri E; Oelofse S; Londt R; Naiker T; Dheda K
    Cancer Immunol Immunother; 2019 Jan; 68(1):71-83. PubMed ID: 30283982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.